RION CoFRA:G73 60 ROE % is 13.57% as of Mar. 2026, which is 50% above its 10-year median of 9.02. GuruFocus rates FRA:G73 with a GF Score™ of 60/100 and a GF Value™ of €14.25 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 799 Medical Devices & Instruments companies, RION Co ranks better than 74.97% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. RION Co's annualized net income for the quarter that ended in Mar. 2026 was €23.9 Mil. RION Co's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was €176.3 Mil. Therefore, RION Co's annualized ROE % for the quarter that ended in Mar. 2026 was 13.57%.
The historical rank and industry rank for RION Co's ROE % or its related term are showing as below:
FRA:G73'
s ROE % Range Over the Past 10 Years
Min: 6.93 Med: 9.02 Max: 10.23
Current: 10.23
During the past 13 years, RION Co's highest ROE % was 10.23%. The lowest was 6.93%. And the median was 9.02%.
FRA:G73's ROE % is ranked better than 74.97% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs FRA:G73: 10.23
RION Co (FRA:G73) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
RION Co ROE % Related Terms
RION Co ROE % Historical Data
* Premium members only.
The historical data trend for RION Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, RION Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RION Co ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RION Co's ROE % distribution charts can be found below:
* The bar in red indicates where RION Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
RION Co (FRA:G73) has a ROE % of 13.57% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on RION Co and its competitors. This is 50% above median its historical median of 9.02. Over the past decade, RION Co's ROE % has ranged from 6.93 to 10.23. According to the industry distribution chart, RION Co ranks #200 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 25%.
Is RION Co's ROE % too high?
RION Co's current ROE % of 13.57% is 50% above median its 10-year median of 9.02. Over the past 10 years, this metric has ranged from a low of 6.93 to a high of 10.23. The Medical Devices & Instruments industry median ROE % is 2.42. RION Co's value of 13.57% is 460.7% above this industry median. Based on the distribution chart, RION Co ranks #200 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, RION Co has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RION Co's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RION Co ranks #200 out of 799 companies for ROE %. This places RION Co in the top 25% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. RION Co's value of 13.57% is 460.7% above this benchmark. Historically, RION Co's own ROE % has ranged from 6.93 to 10.23 over the past decade. While the company's 10-year median is 9.02 vs. the industry median of 2.42, RION Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RION Co's current ROE % of 13.57% is 460.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on RION Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RION Co's current ROE % is 13.57%, which is 50% above median its own 10-year median of 9.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RION Co stock overvalued right now?
Based on GuruFocus' analysis, RION Co (FRA:G73) is currently considered Significantly Overvalued. The stock's GF Value™ is €14.25, compared to a current price of €20.80 — trading 46% above its estimated fair value. The current ROE % is 13.57%, which is 50% above median its 10-year median of 9.02 and 460.7% above the Medical Devices & Instruments industry median of 2.42. RION Co's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For RION Co (FRA:G73), the current ROE % is 13.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RION Co (FRA:G73) Overvalued in 2026?
Based on GuruFocus' analysis, RION Co stock appears to be overvalued.
The current stock price of €20.80 is trading 46% above its estimated GF Value™ of €14.25.
GuruFocus considers RION Co to be Significantly Overvalued.
Key valuation signals for FRA:G73:
ROE %: 13.57% (50% above median its 10-year median of 9.02)
GF Value™: €14.25 vs. price of €20.80 (46% above fair value)
Industry Position: 460.7% above the Medical Devices & Instruments median (#200 of 799)
No single metric tells the full story. See the FRA:G73 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RION Co Ltd is engaged in manufacturing and selling of maintenance services of a medical device. The company offers hearing instruments and medical equipment, an environmental device including sound and vibration measuring instruments and particle counters and parts and equipment.
60GF Score
Get the complete analysis for FRA:G73
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:G73 has been successfully added to your 
